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ing to the CONAPO’s Mexican population projection with 40 years old or over, the 
prevalence of the COPD in Mexico (PLATINO study) and the proportion of people 
that uses biomass for cooking. A deterministic sensitivity analysis was performed 
in both cases. Results: Annual cost of glycopyrronium bromide monotherapy was 
US$265.27 and for tiotropium bromide monotherapy was US$242.30 in one year 
horizon with a percent difference of 10.16% per patient. The budget impact costs 
in the first year were $287,409,746.74 and $262,527,500.25 for tiotropium bromide 
monotherapy and glycopyrronium bromide monotherapy respectively, with savings of 
9.5% using glycopyrronium bromide monotherapy. ConClusions: Glycopyrronium 
bromide monotherapy is less costly than tiotropium bromide monotherapy which 
shows us that is possible to achieve cost-savings with at least the same clinical ben-
efit from the perspective of the Mexican public health system, in specific from IMSS. 
*IMSS (Mexican Institute of Social Security) *CONAPO (National Council of Population) 
*Exchage rate 14.55 MXN
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objeCtives: To estimate annual loss of productivity costs attributable to being over-
weight or having obesity in working US adults with asthma patients. Methods: This 
study applied a cross-sectional design using the 2008-2012 Medical Expenditure Panel 
Survey (MEPS). Asthma patients (18-64 years old) were identified by self-reported 
diagnosis, Clinical Classification Codes of 128, or ICD-9-CM code of 493. To investigate 
the impact of being overweight or having obesity, patients were classified as normal-
weight (18.5≤ BMI< 25), overweight (25≤ BMI< 30), and obese (BMI≥ 30). Productivity 
loss costs, which were measured based on missed work days due to illness or injury 
for one year and the hourly wage, were estimated using a two-part model to adjust 
for patients with zero costs. To estimate the productivity loss costs attributable to 
being overweight or obese, each group of costs was estimated by assuming every-
body is overweight or obese; these costs were then re-estimated by assuming eve-
rybody was normal, and the mean difference between the two estimated costs was 
calculated. All costs were converted to 2013 US dollars using the Consumer Price 
Index (CPI). Results: Among a total of 5,391 working adults with asthma, preva-
lence of normal-weight was 28.9%, overweight 31.4%, and obese 39.7%. Annual aver-
age productivity loss costs for normal, overweight, and obesity in asthma patients 
were $360(95%CI:$297-$423), $461(95%CI:$374-$548), and $753(95%CI:$620-$886) per 
patient, respectively. Among patients with asthma who had loss of productivity costs, 
those with obesity had 1.33 times greater productivity loss costs than normal-weight 
patients. Thus, the productivity loss costs attributable to being overweight or obesity 
in working asthma patients were estimated at $24(95%CI:$24-$25) or $190(95%CI:$184-
$196) per patient per year, respectively. ConClusions: The loss of productivity costs 
among US asthma patients is substantial, which is only further amplified by the 
presence of obesity. This study highlights the importance of obesity control in order 
to reduce burden of asthma treatment and enhance productivity.
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objeCtives: Chronic urticaria (or chronic hives) can be inducible or spontaneous 
(CSU). Data supporting the impact of CSU on patients and comparisons with other 
dermatological diseases are scarce. This study evaluated economic burden associated 
with CSU relative to psoriasis (PsO) among the adults in 5 European (5EU) countries 
and United States (US). Methods: Data from diagnosed chronic hives (used as proxy 
for CSU) and PsO patients collected in the National Health and Wellness Survey (2010-
11 & 2013) for 5EU and (2010-12) for US were used for this retrospective, cross-sectional 
analysis. Outcome measures included the Work Productivity and Activity Impairment 
questionnaire (WPAI) and self-reported healthcare use in prior 6 months. Bivariate 
analysis (t-tests for continuous and chi-square for categorical variables) was used to 
compare patients with CSU vs. PsO. Results: Study included 1,516 patients with CSU 
(769 EU; 747 US) and 12,964 patients with PsO (7,857 EU; 5,107 US). In EU, employed 
CSU patients reported higher absenteeism (10.5% vs. 6.8%), presenteeism (27.4% vs. 
20.5%), overall work impairment (32.6% vs. 24.6%) and activity impairment (39.5% vs. 
30.5%) compared to PsO patients. Similarly, US CSU patients reported higher WPAI 
parameters (8.6% vs. 4.6%), (25.6% vs. 19.1%), (28.9% vs. 21.4%) and (38.9% vs. 31.2%), 
respectively (p< 0.01 for all). CSU patients had more hospitalizations (0.43 vs. 0.17), 
and more visits to ER (0.75 vs. 0.25), physician (3.08 vs. 2.52) and allergist (0.21 vs. 0.06) 
compared to PsO patients (p< 0.001 for all) in EU. Similarly, US CSU patients showed 
more hospitalizations (0.26 vs. 0.15), ER visits (0.42 vs. 0.25), physician (1.46 vs. 1.24) 
and allergist (0.25 vs. 0.09) visits than PsO patients (p< 0.05 for all). ConClusions: 
This analysis of patient reported data show that CSU has a similar or even higher 
economic burden than PsO patients in both EU and US patient population.
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patients. As the results were mainly driven by the lower rates of severe exacerbations 
in the tio arm, this highlights the importance of exacerbations when assessing cost-
effectiveness in moderate to very severe COPD. Overall, a broader range of evidence 
parameters should be considered in economic modelling of COPD.
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objeCtives: Patients with severe refractory asthma experience persistent symptoms 
despite adhering to guideline-based therapies, and they utilize a disproportionate 
share of asthma healthcare resources. Several new treatments are available that 
have been shown to improve symptoms and quality of life in patients with refrac-
tory asthma. The objective of this study was to determine the cost effectiveness of 
primary medical treatment strategies for severe refractory asthma, including biologic 
therapies and follow-on bronchial thermoplasty. Methods: A decision tree analytic 
model to investigate the comparative effect of two biologic therapies and follow-on 
bronchial thermoplasty on asthma exacerbation-related costs and utilities. Endpoints 
of interest were ER visits, hospitalizations, death, and direct healthcare costs. Base-
case inputs were taken from prior literature or assumed as necessary. We used a 
U.S. healthcare perspective, a hypothetical cohort of 10,000 adult refractory asthma 
patients, an annual cycle, and 10-year time horizon to construct our model. Results: 
Among patients who respond to biologic treatment, the addition of bronchial thermo-
plasty was not cost-effective. Mepolizumab without bronchial thermoplasty was the 
most cost-effective option for biologics responders, with a 10-year-per-patient cost of 
$116,776 and 5.46 QALYs gained (ICER $21,388). Among patients who do not respond 
to biologic treatment, bronchial thermoplasty is a cost effective treatment option 
($33,161/QALY). Sensitivity analysis shows that the model is reactive to changes in 
medication cost; a 10% increase in mepolizumab cost results in only omalizumab 
alone or with bronchial thermoplasty being cost-effective. ConClusions: In a 
hypothetical cohort of refractory asthma patients over a 10-year period, it is not cost 
effective to add bronchial thermoplasty to biologic responders’ therapy; however, in 
biologic non-responders, bronchial thermoplasty remains a cost effective add-on 
treatment option. Future studies should incorporate long-term efficacy inputs of 
bronchial thermoplasty and real-world mepolizumab cost data to address assump-
tions necessary due to limited data currently availability for these newer therapies.
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bACKGRounds: Smoking cessation medications have been shown to yield higher 
success rates and sustained abstinence when compared to unassisted quit attempts. 
Although unassisted smoking cessation is still common in Japan, various treat-
ments, including nicotine replacement therapy (NRT) and varenicline, can be 
covered by the health insurance system. objeCtives: To compare the health and 
economic consequences in Japan of using pharmacotherapy to support smoking ces-
sation with unassisted attempts and the current mix of strategies used. Methods: 
A discrete event simulation model was developed, which included multiple quit 
attempts and relapses. The risk of developing smoking-related diseases was esti-
mated based on the duration of smoking abstinence. Data collected from a survey 
conducted in Japan was used to determine the interventions selected by smokers 
initiating a quit attempt, along with the time between multiple quit attempts. The 
analyses were conducted from healthcare payers’ perspective, with supplemental 
analyses in which productivity losses due to smoking-related diseases were esti-
mated. Time horizon was set to lifetime. Results: Using pharmacotherapy (NRT 
or varenicline) to support quit attempts proved to be dominant when compared 
with unassisted attempts or the current mix of strategies (most are unassisted). If 
varenicline is always chosen as the first choice for a quit attempt, it would save JPY 
206,100 and prolong 0.08QALY per smoker over a lifetime horizon, compared to cur-
rent mix of strategies. The greatest cost saving was observed for the smokers aged 
from 40 to < 50 years. ConClusions: Increased utilization of smoking cessation 
pharmacotherapy to support quit attempts is estimated to be cost-saving, as well 
as to improve health outcomes of the many smokers who want to quit.
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objeCtives: To perform a cost-minimization analysis and budget impact of gly-
copyrronium bromide monotherapy versus tiotropium bromide monotherapy as a 
maintenance treatment in adult patients with moderate to severe chronic obstructive 
pulmonary disease (COPD) from the perspective of the Mexican public healthcare 
system. Methods: Using data from GLOW 5 study, it was established the equiva-
lence of safety and efficacy of glycopyrronium bromide monotherapy and tiotropium 
bromide monotherapy, so it is evaluated the annual costs of each therapy to establish 
the cost-savings with glycopyrronium bromide monotherapy. COPD drug cost was 
estimated for one year in the cost-minimization analysis, using local prices for public 
healthcare institutions (IMSS). It was developed a 5 year horizon budget impact from 
the perspective of the Mexican public healthcare system with an annual discount 
rate of 5%. The total population used for the budget impact was calculated accord-
